Tiffany, Kors to Re...
Health Care: Drugs
Telik Inc. (TELK: NASDAQ)
$1.30 -0.02 | -1.52%
05/24/13 - 03:57 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 4.75M | 9.05M | 7.77M | 12.25M |
| Receivables | 5.00K | 25.00K | 214.00K | 216.00K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 5.38M | 12.06M | 24.47M | 44.06M |
| Property, Plant & Equipment, Gross | 0.00 | 1.68M | 1.78M | 6.26M |
| Accumulated Depreciation & Depletion | 0.00 | 1.67M | 1.76M | 4.84M |
| Property, Plant & Equipment, Net | 0.00 | 1.00K | 11.00K | 1.42M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 250.00K | 347.00K | 546.00K | 674.00K |
| Total Non-Current Assets | 250.00K | 348.00K | 557.00K | 2.09M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 5.63M | 12.41M | 25.03M | 46.15M |
| Accounts Payable | 151.00K | 109.00K | 932.00K | 190.00K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 1.02M | 1.46M | 1.44M | 0.00 |
| Total Current Liabilities | 2.12M | 2.64M | 3.74M | 4.84M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 441.00K | 1.47M | 2.92M | 376.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 441.00K | 1.47M | 2.92M | 376.00K |
| Total Liabilities | 2.57M | 4.11M | 6.66M | 5.22M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 3.06M | 8.30M | 18.37M | 40.93M |
| Common Par | 27.00K | 545.00K | 536.00K | 534.00K |
| Additional Paid In Capital | 551.34M | 548.08M | 546.14M | 543.99M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -548.30M | -540.33M | -528.31M | -503.58M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | -1.00K | -2.00K |
| Total Capitalization | 3.06M | 8.30M | 18.37M | 40.93M |
| Total Equity | 3.06M | 8.30M | 18.37M | 40.93M |
| Total Liabilities & Stock Equity | 5.63M | 12.41M | 25.03M | 46.15M |
| Total Common Shares Outstanding | 2.69M | 1.82M | 1.79M | 1.78M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 2.19M | 1.80M | 1.78M | 1.78M |
| Diluted Weighted Shares Outstanding | 2.19M | 1.80M | 1.78M | 1.78M |
| Number of Employees | 17 | 22 | 28 | 41 |
| Number of Part-Time Employees | 1 | 1 | 2 | 2 |
Portfolios with TELK
- Portfolio NameUser Type
- Uservlady 1
- ContributorBarron's Insider Purchases ...
- UserASCO 2010
- UserASCO 2009 Nymph's Watch List.
- UserPeter J. Lotti Portfolio 1
- UserPete'spicks
- ContributorBarron's Activist Stocks 11...
- ContributorBarron's Activist Stocks 11...
- UserC070707
- Usergonzomoney
Latest TELK Headlines from TheStreet
- Icahn Should Hang It Up: Activist 10.28.09 | 06:10 am
- Insider Sells $20.2 Million of National Semi 01.16.09 | 09:01 am
- Insider Sells $1.2M of Noven Pharmaceuticals 01.06.09 | 09:01 am
- Feuerstein's Biotech-Stock Mailbag 04.05.08 | 11:04 am
- Feuerstein's Biotech-Stock Mailbag 11.03.07 | 11:11 am
- Monday's Health Winners & Losers 10.15.07 | 04:10 pm
- Feuerstein's Biotech-Stock Mailbag 09.29.07 | 11:09 am
- Telik Fails Ethics Test 08.09.07 | 08:08 am
- These Homebuilder Stocks Could Soar 07.13.07 | 08:07 am
- Stockpickr: How to Trade Like Carl Icahn 06.20.07 | 12:06 am
Press Releases for TELK
- Telik Announces Preliminary Agreement On Design Of Phase 3 Registration Trial Of Telintra® In Low To Intermediate-1 Risk Myelodysplastic Syndrome - PR Newswire 01.22.13 | 05:01 pm
- Telik Announces Orphan Designation Of Telintra® For Treatment Of Myelodysplastic Syndrome - PR Newswire 01.11.13 | 07:01 pm
- Telik Announces Telintra® Clinical Publication At The 54th Annual Meeting Of The American Society Of Hematology - PR Newswire 12.12.12 | 04:12 pm
- Telik Announces The Publication Of Two Reports In The Journal Of Hematology & Oncology Describing The Results Of A Clinical Study Of Telintra® In Combination With Revlimid® And A Genomic Study Designed To Identify Genes That Predict Response To Telintra In Patients With Myelodysplastic Syndrome - PR Newswire 05.15.12 | 06:05 am
- Telik Regains Compliance With Minimum Bid Price Requirement - PR Newswire 04.17.12 | 04:04 pm
- Telik Announces Reverse Split Of Common Stock - PR Newswire 03.30.12 | 01:03 pm
- Telik Announces Expansion Of Phase 2 Trial Of Telcyta In Hematologic Malignancies - PR Newswire 02.21.12 | 09:02 am
- Telik Announces Presentation And Webcast At 14th Annual BIO CEO & Investor Conference - PR Newswire 02.08.12 | 09:02 am
- Telik Announces Presentation And Webcast At 5th Annual OneMedForum Conference - PR Newswire 01.04.12 | 09:01 am
- Telik Announces The Results Of Genetic Signature Studies Of Myelodysplastic Syndrome Patients Likely To Respond To Telintra® (Ezatiostat Hydrochloride, TLK199) At The Annual Meeting Of The American Society Of Hematology - PR Newswire 12.13.11 | 09:12 am
Partner Headlines for TELK
- 5 Stocks Trading Below Net Cash - Part VI - Seeking Alpha 08.28.12 | 09:08 am
- 19 High Growth Micro Cap Stocks Under $10 - Seeking Alpha 01.23.11 | 07:01 am
